Mar 17
At the 2025 SCOPE Summit Conference, industry leaders gathered to discuss the integration of real-world data (RWD) into clinical trials and practice. The panel, featuring Robert DiCicco from TransCelerate Biopharma, Su Chen from MITRE Corp, Jesper Kjaer from Novo Nordisk, Trevan Locke from Duke University, and Chris Decker from CDISC, explored the complexities and opportunities in leveraging RWD for healthcare advancements.
Read the full article from Clinical Trial Vanguard here.
Related Blog Posts
Solving the Clinical Trial Data Problem
In a new LinkedIn article, Janice Chang, CEO of TransCelerate, and Nicholas Brooke, CEO of The Synergist & PFMD, outline how efforts like the Clinical Trial Data Network, supported by TransCelerate through technical expertise and industry-vetted solutions from our Digital Data Flow initiative, aim to make clinical trial information more structured, connected, and accessible across…
The Clinical Trial Enterprise: Can AI Fix It?
Artificial Intelligence (AI) is reasonably well established in discovery and preclinical research, with success in areas such as target identification and molecular modeling. However, in clinical development, adoption has been fragmented and challenging to embed across the lifecycle. Read the full article by Rob DiCicco from Drug Discovery News here.
Redesigning Clinical Trials Using Artificial Intelligence
While tech evangelists often tout artificial intelligence (AI) as healthcare’s silver bullet, the reality in clinical trials is more complex. Adoption has been cautious, shaped as much by concerns around trust and governance as by technical hurdles. Still, beneath the surface, methodical innovation is gaining momentum. AI is beginning to reshape how trials are designed,…